Selected research
Industry Research
Epoprostenol Sodium Drugs Industry Research Report 2026
Market perspective
The global Epoprostenol Sodium Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Epoprostenol Sodium Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Epoprostenol Sodium Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Epoprostenol Sodium Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Epoprostenol Sodium Drugs include GSK, Teva, Sun Pharmaceutical, Johnson & Johnson, Novartis, PanPharmaceuticals, Nichiiko, Laboratorios Normon and LAB UNKNOWN, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Epoprostenol Sodium Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epoprostenol Sodium Drugs Market by Company
GSK
Teva
Sun Pharmaceutical
Johnson & Johnson
Novartis
PanPharmaceuticals
Nichiiko
Laboratorios Normon
LAB UNKNOWN
Fuji Seiyaku Kogyo KK
DREHM Pharma
Campus Pharma
Advanz Pharma Corp
Epoprostenol Sodium Drugs Segment by Type
0.5 mg/Vail
1.5 mg/Vail
Epoprostenol Sodium Drugs Segment by Application
Hospital
Clinic
Epoprostenol Sodium Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epoprostenol Sodium Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epoprostenol Sodium Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epoprostenol Sodium Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Epoprostenol Sodium Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Epoprostenol Sodium Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Epoprostenol Sodium Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.5 mg/Vail
- 1.5 mg/Vail
Applications
- Hospital
- Clinic
Companies covered
- GSK
- Teva
- Sun Pharmaceutical
- Johnson & Johnson
- Novartis
- PanPharmaceuticals
- Nichiiko
- Laboratorios Normon
- LAB UNKNOWN
- Fuji Seiyaku Kogyo KK
- DREHM Pharma
- Campus Pharma
- Advanz Pharma Corp
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Epoprostenol Sodium Drugs Market Size (2021-2032)
- 2.2.2 Global Epoprostenol Sodium Drugs Sales (2021-2032)
- 2.2.3 Global Epoprostenol Sodium Drugs Market Average Price (2021-2032)
- 2.3 Epoprostenol Sodium Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 0.5 mg/Vail
- 2.3.3 1.5 mg/Vail
- 2.4 Epoprostenol Sodium Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Epoprostenol Sodium Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Epoprostenol Sodium Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Epoprostenol Sodium Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Epoprostenol Sodium Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Epoprostenol Sodium Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Epoprostenol Sodium Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Epoprostenol Sodium Drugs, Product Type & Application
- 3.8 Global Manufacturers of Epoprostenol Sodium Drugs, Established Date
- 3.9 Global Epoprostenol Sodium Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Epoprostenol Sodium Drugs Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Epoprostenol Sodium Drugs Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Sun Pharmaceutical
- 4.3.1 Sun Pharmaceutical Company Information
- 4.3.2 Sun Pharmaceutical Business Overview
- 4.3.3 Sun Pharmaceutical Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sun Pharmaceutical Epoprostenol Sodium Drugs Product Portfolio
- 4.3.5 Sun Pharmaceutical Recent Developments
- 4.4 Johnson & Johnson
- 4.4.1 Johnson & Johnson Company Information
- 4.4.2 Johnson & Johnson Business Overview
- 4.4.3 Johnson & Johnson Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Johnson & Johnson Epoprostenol Sodium Drugs Product Portfolio
- 4.4.5 Johnson & Johnson Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Epoprostenol Sodium Drugs Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 PanPharmaceuticals
- 4.6.1 PanPharmaceuticals Company Information
- 4.6.2 PanPharmaceuticals Business Overview
- 4.6.3 PanPharmaceuticals Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 PanPharmaceuticals Epoprostenol Sodium Drugs Product Portfolio
- 4.6.5 PanPharmaceuticals Recent Developments
- 4.7 Nichiiko
- 4.7.1 Nichiiko Company Information
- 4.7.2 Nichiiko Business Overview
- 4.7.3 Nichiiko Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Nichiiko Epoprostenol Sodium Drugs Product Portfolio
- 4.7.5 Nichiiko Recent Developments
- 4.8 Laboratorios Normon
- 4.8.1 Laboratorios Normon Company Information
- 4.8.2 Laboratorios Normon Business Overview
- 4.8.3 Laboratorios Normon Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Laboratorios Normon Epoprostenol Sodium Drugs Product Portfolio
- 4.8.5 Laboratorios Normon Recent Developments
- 4.9 LAB UNKNOWN
- 4.9.1 LAB UNKNOWN Company Information
- 4.9.2 LAB UNKNOWN Business Overview
- 4.9.3 LAB UNKNOWN Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 LAB UNKNOWN Epoprostenol Sodium Drugs Product Portfolio
- 4.9.5 LAB UNKNOWN Recent Developments
- 4.10 Fuji Seiyaku Kogyo KK
- 4.10.1 Fuji Seiyaku Kogyo KK Company Information
- 4.10.2 Fuji Seiyaku Kogyo KK Business Overview
- 4.10.3 Fuji Seiyaku Kogyo KK Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Fuji Seiyaku Kogyo KK Epoprostenol Sodium Drugs Product Portfolio
- 4.10.5 Fuji Seiyaku Kogyo KK Recent Developments
- 4.11 DREHM Pharma
- 4.11.1 DREHM Pharma Company Information
- 4.11.2 DREHM Pharma Business Overview
- 4.11.3 DREHM Pharma Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 DREHM Pharma Epoprostenol Sodium Drugs Product Portfolio
- 4.11.5 DREHM Pharma Recent Developments
- 4.12 Campus Pharma
- 4.12.1 Campus Pharma Company Information
- 4.12.2 Campus Pharma Business Overview
- 4.12.3 Campus Pharma Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Campus Pharma Epoprostenol Sodium Drugs Product Portfolio
- 4.12.5 Campus Pharma Recent Developments
- 4.13 Advanz Pharma Corp
- 4.13.1 Advanz Pharma Corp Company Information
- 4.13.2 Advanz Pharma Corp Business Overview
- 4.13.3 Advanz Pharma Corp Epoprostenol Sodium Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Advanz Pharma Corp Epoprostenol Sodium Drugs Product Portfolio
- 4.13.5 Advanz Pharma Corp Recent Developments
5 Global Epoprostenol Sodium Drugs Market Scenario by Region
- 5.1 Global Epoprostenol Sodium Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Epoprostenol Sodium Drugs Sales by Region: 2021-2032
- 5.2.1 Global Epoprostenol Sodium Drugs Sales by Region: 2021-2026
- 5.2.2 Global Epoprostenol Sodium Drugs Sales by Region: 2027-2032
- 5.3 Global Epoprostenol Sodium Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Epoprostenol Sodium Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Epoprostenol Sodium Drugs Revenue by Region: 2027-2032
- 5.4 North America Epoprostenol Sodium Drugs Market Facts & Figures by Country
- 5.4.1 North America Epoprostenol Sodium Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Epoprostenol Sodium Drugs Sales by Country (2021-2032)
- 5.4.3 North America Epoprostenol Sodium Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Epoprostenol Sodium Drugs Market Facts & Figures by Country
- 5.5.1 Europe Epoprostenol Sodium Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Epoprostenol Sodium Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Epoprostenol Sodium Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Epoprostenol Sodium Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Epoprostenol Sodium Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Epoprostenol Sodium Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Epoprostenol Sodium Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Epoprostenol Sodium Drugs Market Facts & Figures by Country
- 5.7.1 South America Epoprostenol Sodium Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Epoprostenol Sodium Drugs Sales by Country (2021-2032)
- 5.7.3 South America Epoprostenol Sodium Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Epoprostenol Sodium Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Epoprostenol Sodium Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Epoprostenol Sodium Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Epoprostenol Sodium Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Epoprostenol Sodium Drugs Sales by Type (2021-2032)
- 6.1.1 Global Epoprostenol Sodium Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Epoprostenol Sodium Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Epoprostenol Sodium Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Epoprostenol Sodium Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Epoprostenol Sodium Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Epoprostenol Sodium Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Epoprostenol Sodium Drugs Sales by Application (2021-2032)
- 7.1.1 Global Epoprostenol Sodium Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Epoprostenol Sodium Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Epoprostenol Sodium Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Epoprostenol Sodium Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Epoprostenol Sodium Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Epoprostenol Sodium Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Epoprostenol Sodium Drugs Value Chain Analysis
- 8.1.1 Epoprostenol Sodium Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Epoprostenol Sodium Drugs Production Mode & Process
- 8.2 Epoprostenol Sodium Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Epoprostenol Sodium Drugs Distributors
- 8.2.3 Epoprostenol Sodium Drugs Customers
9 Global Epoprostenol Sodium Drugs Analyzing Market Dynamics
- 9.1 Epoprostenol Sodium Drugs Industry Trends
- 9.2 Epoprostenol Sodium Drugs Industry Drivers
- 9.3 Epoprostenol Sodium Drugs Industry Opportunities and Challenges
- 9.4 Epoprostenol Sodium Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst